Liquidia Technologies has spun out a new biotech company in Research Triangle Park, NC, which boasts an early-stage ophthalmology program and $25 million in venture backing from some high-profile investors.
Back in September, when Ultragenyx CEO Emil Kakkis was talking to FierceBiotech about the company for our annual Fierce 15 report, the biotech chief confidently predicted that he could take the company public next year.
San Diego-based Sangart has gone missing in action after apparently burning through more than a quarter-billion dollars of Leucadia National cash.
ImmunGene is working to get its lead armed-antibody cancer treatment from the lab to the clinic, and now the California company has $9 million in Series A cash to light the way.
A pair of prominent pharma players are partnering up with a few marquee European VCs to back an up-and-coming immunotherapy biotech based in Vienna.
As biotech venture funding plods along at a middling pace, A-list investor OrbiMed has bagged $735 million for its 5th fund, cash earmarked for life sciences companies across all stages of development.
Biopharma backer NovaQuest has closed a $459 million fund, cash the company will use to push promising, late-stage projects toward commercialization.
Fidelity Biosciences is placing a big bet on gene therapy, funding the launch of startup Dimension Therapeutics with some licensed patents and a plan to develop novel treatments for hemophilia.
A pair of scientifists with deep roots in the Alzheimer's field is partnering up with two high-profile antibody development experts with a well-developed platform technology to launch a new biotech with ambitious plans to build a pipeline of new medications to combat the memory-wasting disease. And they're getting $10 million in seed cash from two marquee venture groups to get everything going.
Over the last few months, Carlos Paya has been filling out his management team at Seattle-based Immune Design. And today the biotech CEO detailed an injection of $32.5 million in venture cash--with the near-term prospect of adding $16.5 million more--to finance the biotech's efforts to nail proof-of-concept data on its two top cancer vaccines.